IgA Nephropathy clinical trials
24 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- Study of Ravulizumab in Pediatric Participants With Primary IgAN
- A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
- A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
- Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
- Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
- Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
- PS-002 for the Treatment of IgA Nephropathy in Adults
- Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
- Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
- Study of BHV-1400 in IgA Nephropathy
- Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
- Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
- Atacicept in Multiple Glomerular Diseases
- Study of WAL0921 in Patients With Glomerular Kidney Diseases
- Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
- A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
- Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
- Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
- Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
- Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “IgA Nephropathy” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.